Human PDE4A1A (GenBank Accession No. U97584), full length with N-terminal GST-tag, MW= 100 kDa, expressed in a Baculovirus infected Sf9 cell expression system.

P27815

PDE4A1A, phosphodiesterase 4A1A

≥ 9,400 pmol/min/µg

One unit is defined as the amount of enzyme that will convert 1 pmole of 3', 5'-cAMP to 5'-AMP per minute at 37°C.

Assayed using BPS's PDE4A Assay Kit, Cat. # 60340. Assay conditions: 10 mM Tris-HCl, pH 7.4, 10 mM MgCl₂, 0.1 mg/ml BSA, 0.05% Tween-20, 200 µM cAMP, 2.5 kU 5'-nucleotidase, and serial dilutions of PDE4A1A at 37°C for 20 min. Quantified by 5'- nucleotidase cleaving the 5' -AMP product and releasing the phosphate group which is detected by Malachite Green Reagent.

40 mM Tris-HCl, pH 8.0, 110 mM NaCl, 2.2 mM KCl, 3 mM DTT, 20% glycerol, and 16 mM glutathione

Aqueous buffer solution

>6 months at -80°C.

Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.

1. Sullivan,M., et al., Journal Biochem. J. 333:693-703 (1998).
2. Huston, E., et al., J Cell Sci. 119:3799-810. (2006).

Application Reference(s):
1. Genetic deletion and pharmacological inhibition of phosphodiesterase 10A protects mice from diet-induced obesity and insulin resistance (2014)
2. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey (2013)

Avoid freeze/thaw cycles.

PDE

Recombinant Protein